See more : Banca Mediolanum S.p.A. (BMED.MI) Income Statement Analysis – Financial Results
Complete financial analysis of NGL Fine-Chem Limited (NGLFINE.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NGL Fine-Chem Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Medcolcanna Organics Inc. (MCCN.CN) Income Statement Analysis – Financial Results
- Enerflex Ltd. (EFX.TO) Income Statement Analysis – Financial Results
- Keyera Corp. (KEYUF) Income Statement Analysis – Financial Results
- First Steamship Co., Ltd. (2601.TW) Income Statement Analysis – Financial Results
- LivePerson, Inc. (LPSN) Income Statement Analysis – Financial Results
NGL Fine-Chem Limited (NGLFINE.BO)
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, xylazine hydrochloride, and marbofloxacin for animal health applications; and nitazoxanide and atovaquone for human health applications. The company provides various intermediate products and specialty chemicals; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.34B | 2.78B | 3.18B | 2.55B | 1.49B | 1.51B | 1.11B | 960.28M | 962.93M | 883.28M | 788.68M | 555.69M | 361.08M | 353.78M | 278.23M | 246.30M | 126.42M |
| Cost of Revenue | 2.70B | 1.40B | 1.47B | 1.02B | 643.67M | 626.37M | 458.67M | 378.99M | 408.17M | 416.40M | 403.56M | 287.31M | 187.12M | 167.79M | 231.86M | 205.22M | 56.01M |
| Gross Profit | 636.50M | 1.38B | 1.71B | 1.53B | 845.88M | 881.39M | 650.70M | 581.28M | 554.75M | 466.88M | 385.12M | 268.38M | 173.97M | 185.99M | 46.38M | 41.08M | 70.41M |
| Gross Profit Ratio | 19.07% | 49.54% | 53.70% | 59.87% | 56.79% | 58.46% | 58.65% | 60.53% | 57.61% | 52.86% | 48.83% | 48.30% | 48.18% | 52.57% | 16.67% | 16.68% | 55.70% |
| Research & Development | 47.42M | 24.31M | 17.37M | 18.70M | 21.98M | 14.21M | 7.85M | 9.34M | 8.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 62.09M | 54.77M | 38.43M | 32.56M | 34.02M | 25.79M | 18.27M | 15.47M | 14.46M | 12.50M | 9.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 99.61M | 79.56M | 110.28M | 71.26M | 44.58M | 43.82M | 41.55M | 30.22M | 49.49M | 53.01M | 40.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 208.87M | 148.71M | 103.82M | 78.60M | 69.61M | 59.82M | 45.69M | 63.94M | 65.51M | 49.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 55.30M | 106.83M | 12.53M | 846.16K | 7.80M | 7.31M | 2.01M | 347.09K | 0.00 | 5.93K | 1.10M | 23.14K | 112.74K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.75B | 1.15B | 1.13B | 763.31M | 706.97M | 586.39M | 480.72M | 357.32M | 362.39M | 346.22M | 295.88M | 213.87M | 150.45M | 143.39M | 5.24M | 5.84M | 64.91M |
| Cost & Expenses | 2.97B | 2.55B | 2.60B | 1.79B | 1.35B | 1.21B | 939.39M | 736.31M | 770.57M | 762.62M | 699.44M | 501.17M | 337.57M | 311.18M | 237.10M | 211.06M | 120.92M |
| Interest Income | 5.99M | 2.48M | 1.78M | 1.98M | 2.24M | 1.54M | 1.77M | 1.69M | 1.32M | 978.90K | 710.21K | 673.24K | 492.56K | 713.54K | 623.07K | 346.58K | 0.00 |
| Interest Expense | 18.10M | 11.97M | 15.62M | 18.40M | 22.55M | 22.87M | 15.55M | 7.20M | 11.73M | 12.55M | 12.90M | 11.80M | 9.15M | 5.62M | 2.79M | 4.27M | 3.45M |
| Depreciation & Amortization | 116.42M | 112.91M | 103.69M | 83.34M | 81.12M | 63.00M | 45.61M | 30.79M | 27.22M | 25.97M | 23.20M | 19.33M | 13.53M | 9.36M | 7.76M | 7.62M | 5.92M |
| EBITDA | 673.97M | 404.87M | 788.78M | 881.27M | 228.10M | 361.54M | 241.30M | 268.97M | 221.59M | 170.06M | 106.12M | 75.58M | 38.31M | 53.47M | 49.91M | 43.36M | 11.42M |
| EBITDA Ratio | 20.20% | 14.33% | 24.73% | 34.20% | 16.57% | 25.97% | 21.14% | 26.89% | 22.60% | 16.75% | 13.99% | 13.63% | 10.61% | 15.11% | 17.94% | 17.60% | 9.03% |
| Operating Income | 420.98M | 236.66M | 578.27M | 763.26M | 111.59M | 268.40M | 142.76M | 187.00M | 192.36M | 121.98M | 87.17M | 56.40M | 24.78M | 44.11M | 42.15M | 35.74M | 5.50M |
| Operating Income Ratio | 12.62% | 8.51% | 18.21% | 29.93% | 7.49% | 17.80% | 12.87% | 19.47% | 19.98% | 13.81% | 11.05% | 10.15% | 6.86% | 12.47% | 15.15% | 14.51% | 4.35% |
| Total Other Income/Expenses | 123.19M | 36.96M | 87.70M | 12.64M | -18.18M | -19.34M | 8.05M | 4.18M | -13.68M | 7.93M | -22.15M | -10.07M | -7.88M | -4.11M | -2.79M | -4.27M | -3.45M |
| Income Before Tax | 544.17M | 273.62M | 665.97M | 775.90M | 120.72M | 275.67M | 178.03M | 228.14M | 178.68M | 128.59M | 67.09M | 44.44M | 15.63M | 38.49M | 39.36M | 31.48M | 2.05M |
| Income Before Tax Ratio | 16.31% | 9.84% | 20.98% | 30.43% | 8.10% | 18.28% | 16.05% | 23.76% | 18.56% | 14.56% | 8.51% | 8.00% | 4.33% | 10.88% | 14.15% | 12.78% | 1.62% |
| Income Tax Expense | 131.00M | 68.66M | 166.99M | 208.71M | 37.37M | 74.40M | 52.10M | 79.28M | 64.70M | 45.29M | 21.81M | 15.35M | 5.16M | 14.38M | 12.31M | 11.88M | 439.00K |
| Net Income | 413.17M | 204.96M | 498.97M | 567.19M | 83.35M | 201.27M | 125.93M | 148.86M | 113.98M | 83.30M | 45.28M | 29.09M | 10.47M | 24.11M | 27.04M | 19.60M | 1.58M |
| Net Income Ratio | 12.38% | 7.37% | 15.72% | 22.24% | 5.60% | 13.35% | 11.35% | 15.50% | 11.84% | 9.43% | 5.74% | 5.24% | 2.90% | 6.81% | 9.72% | 7.96% | 1.25% |
| EPS | 66.88 | 33.18 | 80.77 | 91.81 | 13.49 | 32.58 | 20.38 | 24.09 | 18.45 | 13.48 | 7.33 | 4.71 | 1.69 | 3.90 | 4.38 | 3.17 | 0.26 |
| EPS Diluted | 66.88 | 33.18 | 80.77 | 91.81 | 13.49 | 32.58 | 20.38 | 24.09 | 18.45 | 13.48 | 7.33 | 4.71 | 1.69 | 3.90 | 4.38 | 3.17 | 0.26 |
| Weighted Avg Shares Out | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.06M |
| Weighted Avg Shares Out (Dil) | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.06M |
Source: https://incomestatements.info
Category: Stock Reports